Systematic review of the economical efficiency of drugs for anapastic lymphoma kinase-positive non-small cell lung cancer
- VernacularTitle:间变性淋巴瘤激酶阳性非小细胞肺癌治疗药物经济性的系统评价
- Author:
Ran QI
1
;
Shengnan GAO
2
;
Xuting LIU
1
;
Yang LIU
1
;
Guoqiang LIU
1
Author Information
1. Dept. of Pharmacy，the Third Hospital of Hebei Medical University，Shijiazhuang 050051，China
2. Hebei Medical and Health Technology Assessment Association，Shijiazhuang 050051，China
- Publication Type:Journal Article
- Keywords:
anapastic lymphoma kinase;
tyrosine kinase inhibitors;
non-small cell lung cancer;
pharmacoeconomic;
systematic
- From:
China Pharmacy
2022;33(11):1368-1373
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically evaluate the economical efficiency of marketed a naplastic lymphoma kinase （ALK）-tyrosine kinase inhibitors （TKI）for the treatment of ALK-positive non-small cell lung cancer （NSCLC）in China ，and to provide a reference for the selection of China ’s medical insurance list and drug pricing. METHODS Computer searches of databases such as CNKI ，Wanfang database ，VIP，PubMed，Embase and the Cochrane Library were conducted to collect pharmacoeconomic evaluation studies of four marketed ALK-TKI （crizotinib，seretinib，aletinib and ensatinib ）in the treatment of ALK-positive NSCLC in China during the inception to July 2021. The qualities of the included literature were evaluated using CHEERS checklist ，and analyzed systematically in terms of both methodological and economic outcomes. RESULTS A total of 6 literatures were included ，with a compliance rate of 71％ to 83％ for the CHEERS list criteria ，and the overall quality of the literature was high. In terms of methodological analysis ，the pharmacoeconomic evaluation methods included in the study were mainly model-based （Markov or partitioned survival models ） and real-world data-based cost-utility analysis. Most research perspectives were health insurance payer and health system perspectives ；all cost types were direct medical costs. In terms of economical efficiency analysis ，compared with chemotherapy plan ，2 studies confirmed that ALK-TKI （crizotinib，seretinib）were not economic ，1 study confirmed ALK-TKI （crizotinib） showed economical efficiency. Seretinib showed relatively higher economical efficiency when compared to other ALK-TKIs. High drug prices were the main factor why ALK-TKI was not economically viable for treating ALK-positive NSCLC. CONCLUSIONS The second-generation ALK-TKI （seretinib， 163.com alectinib） have better economical efficiency than the first-generation ALK-TKI （crizotinib）. The economical efficiency of seretinib is the best among the second-generation · ALK-TKI. The economical efficiency of chemotherapy regimen is better than that of the second-generation ALK-TKI （seretinib）. Economic comparison between chemotherapy and first-generation ALK-TKI （crizotinib）remains controversial.
